Pre­ci­sion drug + di­ag­nos­tics biotech scores mod­est Se­ries A, retro­fitting ex­ist­ing drug for new in­di­ca­tion

A small biotech is go­ing af­ter sep­sis — and it has raised some more mon­ey to ad­vance that goal and get its new­ly-ac­quired drug in­to the clin­ic.

With $52 mil­lion in debt and eq­ui­ty funds via a Se­ries A, pre­ci­sion ther­a­peu­tics out­fit End­point Health (no re­la­tion to End­points News) now has the cap­i­tal to al­so con­sid­er ex­pand­ing in­to au­toim­mune in­di­ca­tions, CEO Ja­son Springs tells End­points News.

The funds will push the biotech’s plat­form and pipeline for­ward, plus move the start­up’s in-li­censed drug to Phase II clin­i­cal tri­als and sub­mit an IND and IDE (In­ves­ti­ga­tion­al De­vice Ex­emp­tion) to the FDA lat­er in 2022, the com­pa­ny said Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER